Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium

ABSTRACT

A method of decreasing the involuntary movements associated with cerebral palsy using clorazepate dipotassium as the active agent.

United States Patent [191 OBrien METHOD OF REDUCING INVOLUNTARY MOVEMENTS ASSOCIATED WITH CEREBRAL PALSY USING CLORAZEPATE DIPOTASSIUM [75] Inventor: George Sivesind OBrien, Lake Forest, Ill.

[73] Assignee: Abbott Laboratories, Chicago, Ill.

[58] Field of Search 424/244 1 Apr. 23, 1974 [56] References Cited UNITED STATES PATENTS 6/1970 Schmitt 424/244 Primary ExaminerStanley J. Friedman Attorney, Agent, or Firm-Robert L. Niblack; Joyce R. Krei [5 7] ABSTRACT A method of decreasing the involuntary movements associated with cerebral palsy using clorazepate dipotassium as the active agent.

1 Claim, No Drawings METHOD OF REDUCING INVOLUNTARY MOVEMENTS ASSOCIATED WITH CEREBRAL PALSY USING CLORAZEPATE DIPOTASSIUM Nil CH-C ozK-KOH The compound can be prepared according to Example 35 of US. Pat. No. 3,516,988.

Clorazepate dipotassium, the dipotassium salt of 7- chloro-2,3dihydro-2-oxo-5-phenyll H-1 ,4- benzodiazepine-3-carboxylic acid, has previously been reported to be useful as an anticonvulsant agent, antidepressant, muscle relaxant, antianxiety agent and as a tranquilizer. (See, for example, U.S. Pat. No. 3,516,988).

It has now been unexpectedly found that when clorazepate dipotassium is administered to cerebral palsy patients in oral doses of from 15 to 90 mg. per day, the involuntary movements associated with cerebral palsy are either greatly reduced or are completely stopped. The marked reduction or cessation of involuntary movements are sustained when the patient is maintained on clorazepate dipotassium.

I claim:

1. A method of reducing the involuntary movement associated with cerebral palsy comprising orally administering to a cerebral palsy patient from 15 to 90 mg.

daily of clorazepate dipotassium.

' a I 1 I F i 

